Full text is available at the source.
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot
Glucagon-like peptide-1 receptor agonists as a promising treatment for fatty liver disease and obesity
AI simplified
Abstract
GLP-1 receptor agonists have shown potential benefits for liver function in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
- GLP-1 receptor agonists are effective in controlling blood sugar levels and promoting weight loss.
- They may improve cardiovascular and kidney function in addition to their metabolic benefits.
- GLP-1 influences glucose metabolism, appetite, and insulin sensitivity, which could affect liver fat deposition.
- Recent advancements include new formulations and dosing options for GLP-1 receptor agonists, expanding their use.
- Emerging dual and triple hormonal agonists may offer future therapeutic strategies for managing MASLD.
AI simplified